SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Passive Stake in Bio-Path Holdings

Armistice Capital, LLC and Steven Boyd have jointly disclosed a 9.99% beneficial ownership stake in Bio-Path Holdings, Inc. as of December 31, 2024, held for investment purposes.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G with the SEC.
• The Reporting Persons beneficially own an aggregate of 613,798 shares of Bio-Path Holdings, Inc. Common Stock.
• This ownership represents 9.99% of the total outstanding Common Stock of Bio-Path Holdings, Inc.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares are held with shared voting power and shared dispositive power by the Reporting Persons.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing disclosing a passive ownership stake. While not directly positive or negative about the company's operations, the presence of a significant institutional investor can be viewed as a neutral to slightly positive signal of market interest.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital, LLC, and its managing member, Steven Boyd, may signal confidence in Bio-Path Holdings, Inc.'s long-term prospects.

Future Outlook

NA

Management Comments

• Steven Boyd, as Managing Member of Armistice Capital, LLC, and in his individual capacity, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

NA

Stakeholder Impact

• Shareholders may perceive the disclosure of a significant institutional stake as a positive indicator of investor confidence in Bio-Path Holdings, Inc.

Key Dates

Recommendation

Keywords

BIO-PATH HOLDINGS, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment